Search bioRxiv⌕ Search

Biology subjects

Matsushima, A.

Publications and source records attributed to Matsushima, A..

2 recordsLinked to original sources

Huntington's Disease Produces Multiplexed Transcriptional Vulnerabilities of StriatalD1-D2 and Striosome-Matrix Neurons

Striatal cell-type-specific vulnerability in Huntingtons disease (HD) preferentially affects dopamine D2R-expressing projection neurons (SPNs), compatible with manifest motor symptomatology in HD. Transcriptional studies of striatal striosome-matrix compartmentalization in HD are, however, limited, despite pathologic evidence for striosome vulnerability aligning with early mood symptomatology. We used single-nucleus RNA-sequencing on striatal samples from two murine models, and rare Grade 1 HD patient tissues, to examine striosome and matrix sub-clusters within parent D1 and D2 SPN clusters. In human HD, striosomal SPNs were the most depleted SPN population. Surprisingly, for both mouse models, transcriptomic distinctiveness was diminished more for striosome-matrix SPNs than for D1-D2 SPNs. Compartmental markers were dysregulated so as to cancel endogenous identities as striosomal or matrix SPNs, but markers for D1-D2 exhibited less identity obscuring. The canonical striosome-matrix as well as D1-D2 organizations of the striatum thus are both strongly, but differentially, compromised in HD and are targets for therapeutics.

neuroscience↗

Bisphenol A derivatives act as novel coactivator binding inhibitors for estrogen receptor β

Bisphenol A and its derivatives are recognized endocrine disruptors based on their complex effects on estrogen receptor (ER) signaling. While the effects of bisphenol derivatives on ER have been thoroughly evaluated, how these chemicals affect ER{beta} signaling is not well understood. Herein, we identified novel ER{beta} ligands by screening a chemical library of bisphenol derivatives. Many of the compounds identified showed intriguing dual activities as ER agonists and ER{beta} antagonists. Docking simulations suggested that these compounds act as coactivator binding inhibitors (CBIs). Direct binding experiments using wild-type and mutated ER{beta} demonstrated the presence of a second ligand interaction position at the coactivator binding site in ER{beta}. Our study is the first to propose that bisphenol derivatives act as CBIs, presenting a critical view point for future ER signaling-based drug development.

biochemistry↗